Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

No dose-related or cumulative toxicity was observed with increasing duration of ustekinumab exposure for up to 5 years. Rates of AEs reported in ustekinumab psoriasis trials are generally comparable with those reported for other biologics approved for the treatment of moderate-to-severe psoriasis.